Illumina (ILMN) Will Require 'Significant Investment' to Compete with Sequenom (SQNM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Sequenom (SQNM) Prelim FY12 Revs Come in Ahead of Views
January 7, 2013 6:26 AM ESTSequenom, Inc. (NASDAQ: SQNM) announced preliminary highlights of the Company's 2012 performance and accomplishments.
Initial 2012 Performance Results (unaudited)
* Total revenue of approximately $89 million, growth of approximately 59 percent year-over-year for 2012. The Street was looking for revs of $85.3 million.
* Diagnostic services revenues of approximately $46 million,... More
Illumina (ILMN) to Acquire Verinata Health in $450M Deal
January 7, 2013 5:58 AM ESTIllumina, Inc. (Nasdaq: ILMN) has signed a definitive agreement to acquire Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities, for consideration of $350 million plus up to $100 million in milestone payments through 2015. Upon completion of the acquisition, Illumina will have access to Verinatas verifi® prenatal test, the broadest non-invasive prenatal test (NIPT) available today for high-risk pregnancies, and to the most comprehensive intellectual property portfolio in the non-invasive prenatal test industry. As non-invasive prenatal testing is one of the most rapidly growing areas utilizing next-generation sequencing,... More
